Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.94 |
| ▸ | CHKA | P35790 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL393565 | 1.00 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Bromide SCHEMBL1542160 | 1.00 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Ethane SCHEMBL10432502 | 0.97 | CHRM5 (0.89) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL189 | 0.97 | — | — | |
| SCHEMBL8664726 | 0.97 | CHRM5 (1.00) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Bromide SCHEMBL29466744 | 0.95 | CHRM5 (0.84) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Phosphine SCHEMBL23270013 | 0.94 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Hydrochloric Acid SCHEMBL9013636 | 0.94 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL4405649 | 0.94 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 | |
| Water SCHEMBL19285054 | 0.94 | CHRM5 (0.94) | CHRM5CHKAMAPTSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248296-A1 | DEFECT ENGINEERING IN WIDE BANDGAP PEROVSKITES FOR EFFICIENT AND STABLE FULLY TEXTURED PEROVSKITE-SILICON TANDEM SOLAR CELLS | UNITED STATES DEPARTMENT OF ENERGY | 2025-07-31 | — | — | US | claimed |
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2023147338-A2 | DEFECT ENGINEERING IN WIDE BANDGAP PEROVSKITES FOR EFFICIENT AND STABLE FULLY TEXTURED PEROVSKITE-SILICON TANDEM SOLAR CELLS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2022136049-A2 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2022-06-30 | — | — | WO | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250248296-A1 | DEFECT ENGINEERING IN WIDE BANDGAP PEROVSKITES FOR EFFICIENT AND STABLE FULLY TEXTURED PEROVSKITE-SILICON TANDEM SOLAR CELLS | UNITED STATES DEPARTMENT OF ENERGY | 2025-07-31 | — | — | US | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| CN-112930340-B | New synthetic method of piperazinyl-ethoxy-bromophenyl derivatives and their use in the production of compounds containing them | 法国施维雅药厂 | 2025-01-07 | — | — | CN | disclosed |
| CN-119053608-A | Novel compound, conjugated polymer, method for producing same, composition for film formation, organic thin film, and organic semiconductor element | 东曹株式会社 | 2024-11-29 | — | — | CN | disclosed |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2024-04-11 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1020498-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT PACKARD CO (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1020498-A1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | Hewlett-Packard Company (US) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | CHRM5 177/4885CHKA 1391/4885MAPT 4721/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | CHRM5 3970/4885CHKA 1682/4885MAPT 3354/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CHRM5 2179/4885CHKA 3402/4885MAPT 3873/4885 |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | DDT, PPOX, PDCD2L | CHRM5 3711/4885CHKA 3491/4885MAPT 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.